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Abstract
Background: Drug-induced agranulocytosis, a severe side effect marked by a deficit or absolute
lack of granulocytic white blood cells, is a rare side-effect of the anti-inflammatory drug
sulphasalazine. Mutations in the human neutrophil elastase gene (ELA2), causing increased
intracellular concentration of this serine protease, inhibits neutrophil differentiation in severe
congenital neutropenia (SCN). Since the clinical symptoms of agranulocytosis and SCN are similar,
we hypothesized that it may origin from a common genetic variation in ELA2 or that sulphasalazine
may affect human neutrophil elastase activity and protein expression.
Methods: We screened for genetic differences in ELA2 in DNA from 36 patients who had suffered
from sulphasalazine-induced agranulocytosis, and compared them with 72 patients treated with
sulphasalazine without blood reactions. We also performed in vitro studies of the blood cell lines
HL60 and U937 after sulphasalazine exposure with respect to cell survival index, neutrophil
elastase protein expression and activity.
Results: None of the mutations in ELA2, which previously have been reported to be associated
with SCN, was found in this material. Protein expression of human neutrophil elastase in lymphoma
U937 cells was not affected by treatment with concentrations equivalent to therapeutic doses. Cell
survival of lymphoma U937 and promyelocytic leukemia HL-60 cells was not affected in this
concentration range, but exhibited a decreased proliferative capacity with higher sulphasalazine
concentrations. Interestingly the promyelocytic cells were more sensitive to sulphasalazine than
the lymphoma cell line.
Conclusion: Neutrophil elastase expression and ELA2 mutations do, however, not seem to be
involved in the etilogy of sulphasalazine-induced agranulocytosis. Why sulphasalazine is more toxic
to promyelocytes than to lymphocytes remains to be explained.
Background
Sulphasalazine (SA) has anti-inflammatory, immunosup-
pressive and antibiotic actions, and is a component in the
therapy of Crohn's disease, ulcerative colitis and rheuma-
toid arthritis. Bacterial enzymes in the colon split sul-
phasalazine into sulphapyridine and 5-aminosalicylic
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acid before it is absorbed. Sulphapyridine acts as a sul-
phonamide antibiotic, whereas 5-aminosalicylic acid is
believed to be the anti-inflammatory metabolite. Com-
mon side/toxic effects are vomiting, skin rash and head-
ache. The incidence of the hematological adverse effects
associated with sulphasalazine is generally low, but the
reactions can be severe and sometimes fatal. The risk of
sulphasalazine-induced agranulocytosis, i.e. profoundly
depressed circulating neutrophils is highest within the
first three months of sulphasalazine-treatment, with a
fatality rate of 6.5 % [1]. Clinical symptoms of agranulo-
cytosis include fever, malaise and susceptibility to infec-
tions. Patients with arthritic disorders have a greater risk
of developing sulphasalazine-induced agranulocytosis
than patients with inflammatory bowel diseases.
Severe congenital neutropenia (SCN) and cyclic neutrope-
nia (CN) occur both as inherited and as sporadic diseases.
SCN has a constant low neutrophil number if left
untreated, whereas CN manifests with cyclic oscillations
of neutrophil number with a 21-day cycle. Recently,
diverse heterozygous mutations in ELA2, encoding
human neutrophil elastase, have been identified in a
majority of the cases with CN and two-thirds of the cases
with SCN [2].
In this study, we hypothesized that sulphasalazine-
induced agranulocytosis, with clinical symptoms similar
to congenital neutropenia, may arise from genetic varia-
tion in the human neutrophil elastase gene. We geno-
typed 108 sulphasalazine-treated patients for ELA2, one
third which of had experienced sulphasalazine-induced
agranulocytosis. We, furthermore, tested for cytotoxic
doses of sulphasalazine, and studied protein expression of
human neutrophil elastase in sulphasalazine-treated
blood cell lines.
Methods
Subjects
Patients were treated with sulphasalazine (Salazopyrin,
Pharmacia, Sweden) for inflammatory joint diseases and
inflammatory bowel disease. The cases with sulphasala-
zine-induced agranulocytosis were originally collected
through the Swedish Medical Products Agency's register of
adverse side effects [3]. The control group had been
treated with sulphasalazine without adverse effects for at
least 3 months. From the original patient material consist-
ing of 39 cases and 75 controls, DNA was available for 36
cases and 72 controls. The patient journals were studied
for information concerning neutrophil differentiation in
bone marrow aspirates. The study was approved by the
Ethics Committee of the Medical Faculty at Uppsala Uni-
versity, registration number 95–200.
Mutation analysis
Genomic DNA was extracted from whole blood using
standard techniques. Fragments covering exons 2–5 of
ELA2 were amplified by PCR using primer pairs listed in
Table 1. The selection of exons 2–5 and some of the flank-
ing intron sequences was based on previously reported
mutations in cases with SCN and CN [2,4], as outlined in
Figure 1. Products for exon 2–5 were amplified with 1.5
units of AmpliTaq Gold DNA polymerase (Applied Bio-
systems), activated by 15 min at 95°C followed by 4
cycles 94°C 30 sec, 65°C 30 sec, 72°C 1.5 min and 35
cycles of 94°C 30 sec, 67°C 30 sec, 72°C 1.5 min with a
final extension of 10 min at 72°C. The exception was
amplification of exon 5, where a 2°C lower annealing
temperature was used. All primers contained a consensus
M13 sequence to enable sequencing with the same
primer, included in BigDye Primer sequencing kit from
Applied Biosystems, Stockholm, Sweden. Applied Biosys-
tems 310 analyzer and Sequence Analysis software was
used for all sequencing. Thus, the 36 cases and 72 controls
were analyzed for genetic mutations in ELA2.
Cell culture
The lymphoma cell line U937 and the promyelocytic cell
line HL-60 (American tissue culture collection) were cul-
tured in Dulbeccos modified Eagles Medium, DMEM
(Sigma) supplemented with 10 % fetal bovine serum
(SVA, Uppsala, Sweden), L-glutamine and penicillin-
streptomycin (Sigma).
Western blot
Equal numbers (8 × 106) of U937 cells were grown in 75
cm2 dishes in complete medium containing 0, 125 and
250 µM sulphasalazine for 24 h. For protein isolation,
cells were washed in PBS and lysed in buffer containing
1% Triton X-100, 50 mM Tris-HCl pH 8.0 and protease
inhibitor cocktail (Sigma) and were kept on ice for 30
min. Lysates were centrifuged for 10 min at 10 000 × g,
Table 1: Primer sequences for PCR amplification of ELA2 exon 2–
5 
ELA2 target sequence Primers
Exon 2 F 5'-tgtaaaacgacggccagtgggaggggacaggctccttgg-3'
Exon 2 R 5'-caggaaacagctatgaccaccgggacgcggggtccgagc-3'
Exon 3 F 5'-tgtaaaacgacggccagtcaggcccgtcgccggatggg-3'
Exon 3 R 5'-caggaaacagctatgacctccgtcgcagcctccaccct-3'
Exon 4 F 5'-tgtaaaacgacggccagtgtgacgcgctgacgatctgt-3'
Exon 4 R 5'-caggaaacagctatgaccgcagtaccgggctgggagcg-3'
Exon 5 F 5'-tgtaaaacgacggccagtcagtccagcttccccacctt-3',
Exon 5 R 5'-caggaaacagctatgaccgacctactgaccattttcaac-3'
PCR primers sequences for ELA2 exon 2–5, for following sequencing 
reactions with BigDye primer, Applied Biosystems.BMC Blood Disorders 2004, 4:5 http://www.biomedcentral.com/1471-2326/4/5
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and protein concentration was determined using BioRad
protein assay. Criterion precast gels (BioRad, Sweden)
were used to perform SDS-page with 20 µg protein loaded
per well. After gel transfer to a nitrocellulose membrane,
the membranes were blocked over night in 5 % dry milk
in TBS-Tween. Primary antibody against human neu-
trophil elastase (Calbiochem, Sweden) was diluted
1:1000 in 5 % dry milk in TBS-T. After 2 h incubation, and
four sets of washing, a secondary antibody was added
(1:5000) and blots were developed using ECL (ECL West-
ern blotting system, Amersham, Sweden). Western blot
analysis of human neutrophil elastase expression was per-
formed twice.
Elastase activity assay
Cells (HL-60 and U937) treated with 0, 125, 250 and 500
µM of for 24 h were lysed with 100 µl of buffer containing
100 mM Tris-HCl pH 7.4, 1 mM MgCl2, 0.1 % Triton X-
100. After homogenization, 300 µl of 1.4 M NaCl in 0.1
% Triton X-100 was added and samples were centrifuged
at 15 000 × g, for 15 min at 4°C. The supernatants were
transferred to new tubes and assayed for elastase activity
using Suc-Ala-Ala-Ala-pNA (Sigma) as a substrate. For
each assay we took 25 µl sample, mixed with 100 µl buffer
containing 100 mM Tris-HCl pH 8.5, 1 M NaCl, 500 mM
MgCl2 and 0.1 % Triton X-100. To this, 50 µl of substrate
was added, to a final concentration 1 µM. After 30 min of
incubation in room temperature, absorbance was read at
405 nm and the concentration was calculated from a
standard curve of elastase (Sigma).
Cell survival index
For the cell viability assay, we used a fluorometric micro-
culture cytotoxicity assay (FMCA) previously described by
Larsson et al [5]. Briefly, 20 000 cells/well were plated in
96-well plates (NUNC, DK) in complete medium with
addition of increased concentrations of sulphasalazine (0,
125, 250, 500, 750 and 1000 µM) and incubated for 72 h
in a humidified atmosphere used in regular cell culturing.
All samples were plated in triplicates and three wells with
cell culture medium served as blanks. As controls we had
cells without additions and cells only with solvent, in this
case 0.5 M NaOH, with equal molarities as in the wells
with the highest sulphasalazine-concentration. At the end
of the 72 h incubation period, plates were centrifuged
(200 × g, 5 min) and medium was aspirated in a microti-
tre plate washer, washed with PBS and 100 µl of 10 µg/ml
of fluorescein diacetate (Sigma, Sweden), was added. This
dye exclusively binds intact cell membranes of viable cells.
After 1 h incubation at 37°C, the fluorescence was read in
the Fluoroscan 2 (Labsystems OY, Finland) at 480 nm
excitation and 530 nm as emission. The results are pre-
sented as survival index, defined as fluorescence in test
wells/ fluorescence in control wells (blank values sub-
tracted) × 100. Thus, a low numerical value indicates high
sensitivity to the cytotoxic effect of sulphasalazine. Effec-
tive concentration is defined as the concentration when
50 % of the cells are viable (EC50).
Statistics
Two-tailed Student's t-test was used to compare subject
characteristics and results from cell culture between cases
and controls. Frequencies of subject characteristics male
versus females was tested with Chi2-test with one degree
of freedom, using Minitab 14. A p-value less than 0.05 was
denoted with (*), p < 0.01 with (**) and was considered
as statistically significant.
Results
Subjects
The characteristics of the subjects are presented in Table 2.
The agranulocytosis cases were significantly older than the
control patients (p = 0.023). The white blood cell count
(WBC) before sulphasalazine-treatment did not differ
between cases and controls, nor did the dose of sul-
phasalazine. Bone marrow aspirates had been taken from
10 patients (cases). In all samples, the myelopoesis was
seriously reduced and a maturation arrest at the promye-
locyte-myelocyte stage of neutrophilic differentiation was
seen.
Outline of reported mutations in ELA2 exon-sequences in patients with severe congenital neutropenia and cyclic neutropenia Figure 1
Outline of reported mutations in ELA2 exon-sequences in patients with severe congenital neutropenia and 
cyclic neutropenia Outline of mutations previously reported [2, 4] in ELA2 exons 1–5. The SNP S173 [6] is indicated as an 
extended arrow and represents base number 4890 in accession number Y00477 and is a base C→A substitution.
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5
Figure 1BMC Blood Disorders 2004, 4:5 http://www.biomedcentral.com/1471-2326/4/5
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Mutation analysis
None of the previously reported mutations in ELA2 was
found in this material, although we found a silent single
nucleotide polymorphism, called S173 [6] that corre-
sponds to a C4890A substitution in Genbank accession
number Y00477 (marked with extended arrow in Figure
1). The incidence of the S173 polymorphism did not dif-
fer between controls and cases, 0.31 for both, and S173
has previously been detected in healthy subjects [6]. No
correlation between the S173 polymorphism and white
blood count before sulphasalazine-treatment was found
(Table 3).
Elastase expression, elastase activity and cell survival after 
sulphasalazine exposure to HL-60 and U937
By western blot analysis, we analyzed neutrophil elastase
protein expression in U937 cells. No difference in human
neutrophil elastase expression was detected after treat-
ment with 125 and 250 µM sulphasalazine (Figure 2),
compared to controls. The elastase activity in HL-60 and
U937 cells was not affected by increasing sulphasalazine
concentration, ranging from 0 to 500 µM, and expressed
as elastase activity/µg protein (data not shown). For the
cell survival index, each FMCA experiment was performed
three times separately with similar results (inter-assay var-
iation less than 10 %). Concentrations below 250 µM sul-
phasalazine did not affect the survival index of U937 and
HL-60 cells (Figure 3A,3B), but at 500 µM of sulphasala-
zine, the survival index of HL-60 cells decreased to a third
(Figure 3A). The U937 was only marginally affected at 500
µM sulphasalazine-concentration, but cellular survival
decreased with approximately 40 % at 750 µM of sul-
phasalazine (Figure 3B). The effective concentration
(EC50) of sulphasalazine was approximately 370 µM for
HL-60 cells and 820 µM for U937 cells.
Discussion
Idiosyncratic drug-induced agranulocytosis can be due to
several different mechanisms of action, including immu-
nological, toxic and genetic [7,8]. Toxic drug-induced
neutropenia is often dose-dependent, whereas
immunological and genetic causes are less related to dose.
In our study, bone marrow aspirates from patients with
sulphasalazine-induced agranulocytosis revealed matura-
Table 2: Characteristics of subjects 
Cases (n = 36) Controls (n = 72) p-value
Age range (median) 11–77 (55) 13–90 (47) 0.023
WBC before a 9.3 ± 4.7 8.5 ± 2.5 0.26
Dose of sulphasalazine (gram/day) 2.2 ± 0.6 2.0 ± 0.4 0.13
Male : Female 17 : 19 33 : 39 0.891
a WBC data only available for 28 cases and 67 controls.
Cases are defined as the patients treated with sulphasalazine, who were diagnosed with agranulocytosis and controls were defined as patients 
treated with sulphasalazine without hematological side effects within the first three months of sulphasalazine treatment. The statistics of differences 
between cases and controls in age, white blood cell count (WBC) before sulphasalazine treatment and dose of sulphasalazine was calculated with 2-
tailed Student's t-test. The frequency of males versus females was calculated with Chi2 test, one degree of freedom. Significance level was set at 
0.05.
Western blot analysis of human neutrophil elastase (hNE)  expression after sulphasalazine exposure Figure 2
Western blot analysis of human neutrophil elastase 
(hNE) expression after sulphasalazine exposure U937 
cells were incubated for 24 h with 0, 125 and 250 µM sul-
phasalazine, followed by cell lysis and protein isolation. 20 µg 
of protein was applied in each lane, transferred to nitrocellu-
lose membrane and incubated with human neutrophil 
elastase antibody.
hNE 35 kDa
0 125 250
Sulphasalazine (µM)
Figure 2
Table 3: White blood count (WBC), before sulphasalazine 
treatment, in subjects with or without the S173 polymorphism 
WBC
Subjects with S173 (n = 34) 8.74 ± 2.51
Subjects without S173 (n = 74) 8.66 ± 3.51
White blood count (WBC) was estimated by the local physicians 
before starting with the sulphasalazine treatment. The average WBC 
in subjects with or without S173 is presented as the mean value ± SD. 
It was no statistical difference between the groups.BMC Blood Disorders 2004, 4:5 http://www.biomedcentral.com/1471-2326/4/5
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tion arrest of neutrophils at the promyelocyte-myelocyte
stage. These findings resemble promyelocytic maturation
arrest seen in severe congenital neutopenia (SCN) and
cyclic neutropenia (CN) [9]. In the majority of cases with
SCN and CN, germline mutations in the human neu-
trophil elastase gene (ELA2) are implicated as the primary
abnormality [2,4]. The focus of this study is therefore on
the human neutrophil elastase gene as a possible cause of
sulphasalazine-induced agranulocytosis. We found a cod-
ing synonymous polymorphism in ELA2, which, how-
ever, was equally represented among cases and controls.
Heterozygous mutations in ELA2 act in a dominant man-
ner, interfering with sub-cellular trafficking of neutrophil
elastase, and leading to an accumulation of neutrophil
elastase in the cytosol [10]. For normal neutrophil cell
maturation, the proliferative action of the granulocyte col-
ony stimulating factor (G-CSF) is necessary [11]. When G-
CSF is exposed to active elastase enzyme in vitro, G-CSF is
rapidly cleaved and rendered inactive [11]. In theory, SCN
and CN are caused by an accumulation of neutrophil
elastase, leading to an inactivation of G-CSF and a nega-
tive feedback on granulopoiesis, which causes neutrope-
nia. Other proteins, connected to expression and
transportation of human neutrophil elastase, have also
been linked to SCN disease. In canine cyclic hematopoi-
eses, lack of the intracellular transport protein AP3β
causes accumulation of canine neutrophil elastase in the
cytosolic compartments [12], and mutations in ELA2 may
disrupt the AP3β-recognition site [13]. Furthermore,
mutations in the proto-oncogene GFI1, a transcriptional
repressor of ELA2, causes over-expression of neutrophil
elastase in mice, thus, making them neutropenic [14].
During maintenance therapy with sulphasalazine, trough
serum sulpha concentration is on average approximately
100 µM at the Department of Clinical chemistry and phar-
macology, Uppsala University hospital. To avoid toxic
effects, trough serum concentration of sulpha should stay
below 600 µM [15]. Our in vitro data suggest a decreased
cell survival of sulphasalazine at concentrations around
500 µM. Interestingly promyelocytic leukemia HL-60 cells
were more sensitive to sulphasalazine than lymphoma
U937 cells, with EC50 values of 370 µM and 820 µM,
respectively. Human neutrophil elastase expression in
lymphoma U937 cells did not differ after sulphasalazine
at 125 and 250 µM, indicating that human neutrophil
elastase production is not affected by sulphasalazine at
subtoxic levels.
Conclusions
In conclusion, neutrophil elastase does not appear to be
involved in the etiology of sulphasalazine-induced
agranulocytosis. No causative ELA2  mutations were
found, and therapeutic concentrations of sulphasalazine
did not increase the expression of human neutrophil
elastase. High concentrations of sulphasalazine were toxic
to white blood cells in vitro; however, there is no evidence
that this toxicity is mediated through human neutrophil
elastase. Promyelocytic cells were more sensitive to sul-
phasalazine than lymphoma cells, and the reason for this
difference may also explain sulphasalazine-induced
agranulocytosis.
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Survival index of HL-60 and U937 cells, incubated with  increasing concentrations of sulphasalazine Figure 3
Survival index of HL-60 and U937 cells, incubated 
with increasing concentrations of sulphasalazine Sur-
vival index of HL-60 (A) and U937 cells (B) treated with 
increasing concentrations of sulphasalazine (0–1000 µM) for 
72 h and measured with FMCA. Survival index, defined as flu-
orescence in test wells/ fluorescence in control wells (blank 
values subtracted) × 100.
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